35 related articles for article (PubMed ID: 3937596)
1. The effects of hyperprolactinemia on bone and fat.
Shibli-Rahhal A; Schlechte J
Pituitary; 2009; 12(2):96-104. PubMed ID: 18338266
[TBL] [Abstract][Full Text] [Related]
2. Bone density in women with prolactinoma treated with dopamine agonists.
Naliato EC; Violante AH; Caldas D; Farias ML; Bussade I; Lamounier Filho A; Loureiro CR; Fontes R; Schrank Y; Loures T; Colao A
Pituitary; 2008; 11(1):21-8. PubMed ID: 17661178
[TBL] [Abstract][Full Text] [Related]
3. Reversal of severe osteopenia in a patient with hyperprolactinemia treated with bromocriptine.
Lindberg JS; Kolb FO; Blau RA; Powell MR
West J Med; 1988 Sep; 149(3):341-3. PubMed ID: 3176495
[No Abstract] [Full Text] [Related]
4. Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
Sartorio A; Conti A; Ambrosi B; Muratori M; Morabito F; Faglia G
J Endocrinol Invest; 1990 May; 13(5):419-22. PubMed ID: 1974270
[TBL] [Abstract][Full Text] [Related]
5. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the understanding of the pathophysiology and treatment of hyperprolactinemia.
Sarapura V; Schlaff WD
Curr Opin Obstet Gynecol; 1993 Jun; 5(3):360-7. PubMed ID: 8329652
[TBL] [Abstract][Full Text] [Related]
7. Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia.
Caraceni MP; Corghi E; Ortolani S; Casazza S; D'Alberton A; Motta T
Calcif Tissue Int; 1985 Dec; 37(6):687-9. PubMed ID: 3937596
[TBL] [Abstract][Full Text] [Related]
8. Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment.
Tørring O; Isberg B; Sjöberg HE; Bucht E; Hulting AL
Acta Endocrinol (Copenh); 1993 May; 128(5):423-7. PubMed ID: 8317189
[TBL] [Abstract][Full Text] [Related]
9. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
10. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.
Schlechte J; el-Khoury G; Kathol M; Walkner L
J Clin Endocrinol Metab; 1987 May; 64(5):1021-6. PubMed ID: 3558723
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis in men with hyperprolactinemic hypogonadism.
Greenspan SL; Neer RM; Ridgway EC; Klibanski A
Ann Intern Med; 1986 Jun; 104(6):777-82. PubMed ID: 3706929
[TBL] [Abstract][Full Text] [Related]
12. Prolactin secretion and menstrual function after long-term bromocriptine treatment.
Rasmussen C; Bergh T; Wide L
Fertil Steril; 1987 Oct; 48(4):550-4. PubMed ID: 3653413
[TBL] [Abstract][Full Text] [Related]
13. Decreased bone density in hyperprolactinemic women.
Klibanski A; Neer RM; Beitins IZ; Ridgway EC; Zervas NT; McArthur JW
N Engl J Med; 1980 Dec; 303(26):1511-4. PubMed ID: 7432421
[No Abstract] [Full Text] [Related]
14. Effects of parathyroid hormone infusion and primary hyperparathyroidism on serum prolactin in man.
Castro JH; Caro JF; Kim HJ; Glennon JA
J Clin Endocrinol Metab; 1980 Aug; 51(2):397-8. PubMed ID: 7400304
[TBL] [Abstract][Full Text] [Related]
15. Role of pituitary hormones in regulating renal vitamin D metabolism in man.
Brown DJ; Spanos E; MacIntyre I
Br Med J; 1980 Feb; 280(6210):277-8. PubMed ID: 7357340
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
